PGP and cancer: An additional study that investigated patients with various types of cancer, including CML, demonstrated that the rate of elimination of the P-gp substrate, sestamibi (99mTc), was higher in individuals who carried the 3435CC/2677GG haplotype, suggesting a higher P-gp activity in such patients (29).